DU4475 Xenograft Model Service for Breast Cancer

The DU4475 xenograft model is an invaluable in vivo resource for investigating the complex biology of triple-negative breast cancer (TNBC), particularly for research focused on MAP kinase signaling and unique genetic drivers. Alfa Cytology provides an end-to-end DU4475 xenograft model service, delivering high-quality preclinical data through our specialized surgical techniques and rigorous experimental validation to support your oncology drug development journey.

Overview of DU4475 Xenograft Model for Breast Cancer

The DU4475 cell line is derived from a human breast carcinoma and is recognized as a key model for triple-negative breast cancer (TNBC), lacking the expression of ER, PR, and HER2. What distinguishes DU4475 from many other TNBC models is its unique genetic and phenotypic profile, including its growth as floating aggregates in vitro and its specific mutation status, such as being BRAF mutant. This makes it an essential platform for studying resistance mechanisms and evaluating inhibitors targeting the MAPK/ERK pathway.

When established in vivo as a xenograft, DU4475 cells form aggressive tumors in immunocompromised mice that closely mimic the rapid proliferation and invasive characteristics seen in clinical TNBC cases. The model is highly responsive to various therapeutic interventions, making it suitable for efficacy testing of small molecules, biologics, and novel combination therapies.

Fig 1. Mice with DU4475 tumors were initially administered 0.8 mg or 0.6 mg iMN041 SC in FS-19 qod or PBS (n =10 per group). (Daifuku, R., et al., 2024)

Cell Line Information: DU4475

The DU4475 cell line exhibits typical epithelial morphology and is characterized by its stable growth profile under controlled laboratory conditions.

Alfa Cytology is committed to providing researchers with the highest standard of in vivo modeling. Our team possesses the specialized technical skills required to handle the unique suspension growth characteristics of DU4475 cells, ensuring high viability and consistent tumor engraftment.

Our Services

Workflow of DU4475 Xenograft Model Construction

The construction of a DU4475 xenograft model at Alfa Cytology follows a structured and validated workflow:

• Cell Culture: DU4475 cells are expanded in specialized suspension culture media. We perform rigorous quality control to confirm the BRAF mutation status and ensure the cells are free from mycoplasma before transitioning to animal studies.
• Animal Selection & Acclimatization: Healthy, standardized immunocompromised mice (such as Nude or SCID strains) are selected. Animals undergo a mandatory period of acclimatization in our controlled laboratory environment to ensure physiological stability and minimize stress-induced variability.
• Standardized Inoculation: To address the unique aggregate-growth nature of DU4475, cells are carefully prepared in a high-viability suspension, optimized with a biological matrix carrier to promote effective in vivo engraftment. The mixture is then precisely injected via subcutaneous or orthotopic routes.
• Longitudinal Monitoring: Following inoculation, tumor growth is systematically monitored. We utilize precision instruments to track tumor dimensions and animal body weight, establishing a reliable growth curve while ensuring adherence to animal welfare guidelines.
• Randomization & Study Grouping: Once tumors have established a consistent and statistically significant growth trend, animals are randomized into experimental cohorts. This process ensures balanced group distribution and maximizes the statistical power of the subsequent efficacy evaluation.

Fig 2. DU4475 Xenograft Model Construction Workflow

Case Study - DU4475 Xenograft Model Development

In a recent efficacy study performed by Alfa Cytology, the DU4475 xenograft model was employed to evaluate a targeted BRAF inhibitor. The model demonstrated robust engraftment and a predictable growth rate that allowed for a clear distinction between the vehicle control and treatment groups. The in vivo data revealed significant tumor regression in the treated cohort, which correlated perfectly with the inhibition of downstream signaling markers, providing our client with the high-confidence data required for their clinical development strategy.

Why Choose Alfa Cytology?

• Specialized Handling: Expert knowledge in managing suspension-growth cell lines like DU4475 for in vivo use.
• Genetic Fidelity: Routine verification of mutation profiles to ensure the model remains clinically relevant.
• Customized Endpoints: Flexible study designs including customized dosing routes, PK/PD analysis, and advanced histology.
• Scientific Support: Direct access to PhD-level scientists to assist with study design and data interpretation.

Contact Us

Are you ready to advance your TNBC research with a professionally managed DU4475 xenograft model? Our team at Alfa Cytology is eager to help you achieve your preclinical milestones with precision and speed. Please reach out to us today to discuss your study parameters, or contact us to request a formal proposal and discover how we can add value to your drug discovery program.

For research use only. Not intended for any clinical use.